Antibody-drug conjugate (ADC) CDMOs in Europe: 15 compared (2026)
15 of the 255 contract development and manufacturing organisations in A4BEE’s European census list antibody-drug conjugate (ADC) manufacturing among their capabilities. The largest, with revenue over €1bn, are Almac Group, BSP Pharmaceuticals, Lonza and Olon. 5 sit between €250m and €1bn and 6 are smaller or niche.
By ownership: 5 family-owned, 4 private equity, 2 listed and 4 part of a pharma or industrial group. They are spread across 6 countries, led by Switzerland (4), the United Kingdom (4), Italy (3), Germany (2) and Belgium (1). 9 of the 15 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
15 companies
Antibody-drug conjugate (ADC) CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| Almac Group£400 m+ capex program; broad clinical + diagnostics services alongside API. | Craigavon, United Kingdom | Family-ownedMcClay charitable trust | Tier 1 | £1.027 bn FY2024 | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader. | Basel, Switzerland | Listed | Tier 1 | CHF 6.5 bn (2025) | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and protein | high |
| OlonOne of Europe's largest API CDMOs; absorbed Euticals. Chemical synthesis + microbial fermentation, HPAPI, ADC bioconjugation. | Rodano, Italy | Family-owned | Tier 1 | ~€546 m (2024, group) | Small-molecule API, Microbial and protein, Peptide, Antibody-drug conjugate (ADC), Biologics and biosimilars | high |
| AbzenaIntegrated biologics / bioconjugate / ADC CDMO+CRO, UK-founded but increasingly US-centred — European-HQ status borderline. Fills the ADC/bioconjugation gap. | Cambridge, United Kingdom | Private equityWelsh, Carson, Anderson & Stowe | Tier 2 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC) | low |
| Ajinomoto Bio-Pharma (OmniChem)Small-molecule API CDMO: HPAPIs, ADC conjugation, oligonucleotides, continuous-flow chemistry. | Wetteren, Belgium | Part of a pharma or industrial groupAjinomoto | Tier 2 | not disclosed | Small-molecule API, Peptide, Antibody-drug conjugate (ADC) | high |
| AxploraAPI/HPAPI specialist across German and French sites. | Munich, Germany | Private equity | Tier 2 | n/d | Small-molecule API, Antibody-drug conjugate (ADC) | low |
| Merck KGaA CDMOLife-Science CDMO arm covering biologics, ADC/HPAPI, viral vectors and LNP (via Exelead). | Darmstadt, Germany | ListedE. Merck KG | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Viral vector and vaccine, mRNA and LNP | medium |
| PROCOSCustom synthesis (~70% of turnover) + generic APIs; active in HPAPI and ADC drug-linkers. Owned by Japan's CBC. | Cameri, Italy | Part of a pharma or industrial groupCBC Group (Japan) | Tier 2 | €233.8 m (2024) | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| CARBOGEN AMCISDrug-substance & drug-product CDMO (incl. HPAPI/ADC); Swiss arm of Indian-listed Dishman Carbogen Amcis. | Bubendorf, Switzerland | Part of a pharma or industrial groupDishman Carbogen Amcis (India) | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | medium |
| Cerbios-Pharma~50-year-old CDMO for HPAPIs, ADCs, recombinant proteins and live biotherapeutics; acquired by HAS Healthcare 2025. | Lugano, Switzerland | Private equityHAS Healthcare | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC), Biologics and biosimilars, Microbial and protein | high |
| GTP BiowaysBiologics CDMO (mAbs, proteins, nanodrugs, ADCs, fill-finish). Acquired by Italy's Olon; now Olon France. | Toulouse, France | Part of a pharma or industrial groupOlon Group | Tier 3 | ~€12 m | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Microbial and protein, Sterile fill-finish | high |
| HAS Healthcare Advanced SynthesisEx-Helsinn HPAPI/anticancer API CDMO spun out as independent in 2022; now parent of Cerbios. | Biasca, Switzerland | Family-ownedBraglia family | Tier 3 | not disclosed | Small-molecule API, Antibody-drug conjugate (ADC) | high |
| Sterling Pharma | Cramlington, United Kingdom | Private equityGHO Capital | Tier 3 | ~£130 m FY2023 | Small-molecule API, Antibody-drug conjugate (ADC), Peptide | medium |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe (36)
- Antibody-drug conjugate (ADC) CDMOs in Europe
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)